Sanofi is dropping an experimental drug targeting a pathway that many analysts see as a potential pillar of the next generation of immunology medicine. The company will no longer pursue the program known as SAR448272 ...

This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗